Necessary cookies enable core functionality. Received: 23 July 2017; Accepted: 23 October 2017; Published: 06 November 2017. This study was approved by the Research Ethics Committee at the National Taiwan University Hospital (201706023RINC). 2017 Nov 8;8:1472. doi: 10.3389/fimmu.2017.01472. Leuk Lymphoma. Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: The Role of Desensitizations Front Immunol. (Bruchim et al., 2014) demonstrated safe re-treatment with carboplatin using a desensitization protocol to reduce repeated hypersensitivity reactions, and Koshiba et al. Curr Allergy Asthma Rep. 2023 Jan;23(1):1-11. doi: 10.1007/s11882-022-01052-z. As shown in Table 6, drug or food history (odd ratios [OR] 2.340, 95% confidence interval [CI] 1.374-3.984, P = 0.0018), malignant ascites (OR 1.895, 95% CI 1.1083.241, P = 0.0196), and cumulative carboplatin dose (4,0004,999 mg: OR 5.507, 95% CI 1.79616.887, P = 0.0028; 5,0009,999 mg: OR 7.244, 95% CI 2.74019.149, P < 0.0001; 10,000 mg: OR 8.461, 95% CI 3.00723.806, P < 0.0001; P for trend < 0.0001) significantly positively correlated with carboplatin hypersensitivity. Figure 1. Supportive. 2018 Jun;54(3):375-385. doi: 10.1007/s12016-016-8556-5. Int. Furthermore, Moon et al. In the US, PH FDC SC can be administered by healthcare professionals in patients (pts) homes. Federal government websites often end in .gov or .mil. The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. Platinum-based combination chemotherapy is the recommended treatment for platinum-sensitive recurrent ovarian cancer (Parmar et al., 2003; Pfisterer et al., 2006; Pujade-Lauraine et al., 2010). Discontinuations due to anaphylaxis/hypersensitivity were rare for PH IV (generally <1% except two TRYPHAENA arms: 1% and 3%); no discontinuations of PH FDC SC have been recorded so far. Cancer. This site uses cookies. Supporting your clinical decisions with ESMOs regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession. Check the latest publications and updates here to make sure you dont miss anything. A cumulative carboplatin dose >4,000 mg significantly positively correlated with carboplatin hypersensitivity. It didn't disappoint. doi: 10.1006/gyno.1994.1098, Keywords: ovarian cancer, chemotherapy, carboplatin, hypersensitivity, risk factor, Citation: Tai Y-H, Tai Y-J, Hsu H-C, Lee S-P, Chen Y-Y, Chiang Y-C, Chen Y-L, Chen C-A and Cheng W-F (2017) Risk Factors of Hypersensitivity to Carboplatin in Patients with Gynecologic Malignancies. Epub 2022 Nov 29. Interactive/Pocket Guideline Interactive/Pocket Guideline Constipation in Advanced Cancer 1 2 3 Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. The cumulative incidence of carboplatin-related hypersensitivity reactions increased with the number of carboplatin cycles (Figure 1A) and increasing dose (Figure 1B), especially at >8 cycles or a dose >3,500 mg.

Incorrect Quotes Nsfw Generator, List Of Woke Companies To Avoid, Articles E